Sabinsa Corporation will feature the company’s game-changing Curcumin C3 Reduct® along with two new water-soluble ingredients, one from of Boswellia serrata, called Polybos® and the other called MoringIn™ from Moringa oleifera, at SupplySide Marketplace, Javits Center, New York, April 30 to May 2.
C3 Reduct solves the issues of potency, color, dosage, stability and bioavailability concerns that have kept this highly beneficial herb from achieving the potential the body of science behind it warrants. As a color-free extract with superior solubility and pH stability than curcuminoids, Curcumin C3 Reduct provides more formulation options to manufacturers. With higher bioavailability in the gut compared to parent curcuminoids, tetrahydrocurcuminoids makes a better choice for oral supplementation. Curcumin C3 Reduct can be delivered in a smaller tablet or capsule. Sabinsa's recommended Curcumin C3 Complex dosage is 1,500 mg/daily, but new Curcumin C3 Reduct is recommended at 400 mg/daily.
Sabinsa will introduce Polybos, a water-soluble polysaccharide fraction of the exudates of Boswellia serrata. Polybos displays excellent joint support activity in adjuvant induced arthritic animal models showing reduction odema as well as in markers such as TNF alpha and LTB4. The water-soluble property makes aqueous formulations practical, especially for sports nutritional applications.
Sabinsa will also introduce MoringIn, a completely water-soluble standardized extract from the dried leaves of Moringa oleifera, which contains a minimum of 5 percent Rutin—a flavonoid glycoside. In India it has been used nearly 5,000 years as a food ingredient and medicine. Moringa leaves are known to have a high content of protein, minerals, vitamins, essential amino acids and phytochemicals.